Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sulfatinib T · 1 trial · 1 indication
The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.
Maximum observed concentration, occurring at Tmax.
The time at which maximum plasma concentration (Cmax) is observed.
The time required for the concentration of the drug to reach half of its original value.
This term represents the relationship between the bioavailability of a substance in two different media.
| Arm | Type | Description |
|---|---|---|
| Arm A-Sulfatinib T capsule | EXPERIMENTAL | The subjects in this arm will receive sulfatinib T capsules from Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. |
| Arm B-Sulfatinib R capsule | EXPERIMENTAL | The subjects in this arm will receive sulfatinib R capsules from Beijing Yiling Bioengineering Technology Co., Ltd. |
| Name | Type | Description |
|---|---|---|
| Sulfatinib T capsule | DRUG | Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production. |
| Sulfatinib R capsule | DRUG | Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd. |
Inclusion Criteria: 1. Subjects must be voluntary and sign an informed consent form and agree to comply with the requirements of the protocol； 2. Age of 18-40 (inclusive), male healthy volunteers； 3. Medical history, physical examination, 12-lead ECG and laboratory tests at screening judged as norm...
Sulfatinib T is an investigational small molecule being studied for its relative bioavailability. It is being evaluated in a clinical trial to explore the pharmacokinetics and relative bioavailability of Sulfatinib capsules from two different manufacturers. The drug is in Phase 1 clinical development.
Sulfatinib T is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM. The company is conducting clinical research on this investigational small molecule drug.
Sulfatinib T is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its pharmacokinetics and relative bioavailability.
Sulfatinib T is associated with one completed clinical trial, NCT03483259, titled 'To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers.' This Phase 1 study enrolled 30 male participants in China and was controlled but not double-blinded.
Sulfatinib T is a designation for the drug Sulfatinib, which is being studied in capsule form. The clinical trial NCT03483259 evaluates the relative bioavailability of Sulfatinib capsules from two different manufacturers, indicating that Sulfatinib T refers to this specific formulation or study context.